Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Co-Agonists for Cardioprotection, Type 2 Diabetes and Obesity: a Review of Mechanisms and Clinical Data
GIP receptor co-agonists are in development to capitalize on the synergism of GLP-1 and GIP agonism. We review the mechanisms of action and clinical data for GLP-1/GIP receptor co-agonists in...
GLP-1/GIP receptor co-agonists are a novel addition to the diabetes and obesity armamentarium. The cardiorenal-metabolic benefits position them as promising multiprong tools for metabolically complex individuals with chronic vascular complications.
Share
Early Use of Oral Semaglutide in the UK: a Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy
Source : https://bmjopen.bmj.com/content/13/9/e070473
Objectives Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite...
Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide, being available. The present study evaluated the...
Share
Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
Source : https://pubmed.ncbi.nlm.nih.gov/37762862/
In spite of the widespread use of lifestyle modifications programs, many patients with PCOS are obese and prevalence of obesity in PCOS remains high. In this study, we present the...
In conclusion, treatment with semaglutide, at low doses, significantly reduces body weight in almost 80% of obese PCOS patients who were unresponsive to a previous lifestyle plan. It is often associated with the normalization of menstrual cycles, and these important results are obtained with very few side effects.
Share
Positive additive interaction effects of age, sex, obesity, and metabolic syndrome on left ventricular dysfunction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37743094/
The MetS is independently associated with LVDD and impaired GLS. From the public health implications, prevention of MetS in women, elderly, and obese individuals might result in a greater reduction...
The MetS is independently associated with LVDD and impaired GLS. From the public health implications, prevention of MetS in women, elderly, and obese individuals might result in a greater reduction of LVDD and LVSD risk in cardiovascular high-risk population.
Share
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting - Endocrine
Source : https://link.springer.com/article/10.1007/s12020-023-03534-0
Background Obesity is defined as excess adipose tissue causing a deterioration in health, but diagnosing the causes and deciding on treatment can be challenging. Several randomized controlled clinical trials (RCT)...
Injectable semaglutide in a real-world setting resulted in similar weight loss and had a similar side effect profile as was observed in randomized controlled trials.
Share